{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:34:03Z","timestamp":1790264043438,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.idnow.2026.105312","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:50:05Z","timestamp":1781801405000},"page":"105312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Updated guidelines for management of community-acquired urinary tract infections in adult men by the French infectious disease society (SPILF)"],"prefix":"10.1016","volume":"56","author":[{"given":"Matthieu","family":"Lafaurie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Boutfol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cattoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lesprit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Milacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Orcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Putot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Soudais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2026.105312_bb0005","series-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.idnow.2026.105312_bb0010","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS) [Internet]"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0015","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.amjmed.2016.11.039","article-title":"Bacteriuria\/pyuria of clinically undetermined significance (BPCUS): common, but currently nameless","volume":"130","author":"Johnson","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.idnow.2026.105312_bb0020","first-page":"e437","article-title":"New clinical prediction model for early recognition of sepsis in adult primary care patients: a prospective diagnostic cohort study of development and external validation","volume":"72","author":"Loots","year":"2022","journal-title":"Br J Gen Pract"},{"issue":"469","key":"10.1016\/j.idnow.2026.105312_bb0025","first-page":"833","volume":"42","year":"2022","journal-title":"Prescrire"},{"issue":"3","key":"10.1016\/j.idnow.2026.105312_bb0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/diagnostics11030523","article-title":"Atypical presentation of bacteremic urinary tract infection in older patients: frequency and prognostic impact","volume":"11","author":"Laborde","year":"2021","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000003874","article-title":"Proposing the \u201ccontinuum of UTI\u201d for a nuanced approach to diagnosis and management of urinary tract infections","volume":"211","author":"Advani","year":"2024","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0040","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1086\/521254","article-title":"Evaluation of the nitrite and leukocyte esterase activity tests for the diagnosis of acute symptomatic urinary tract infection in men","volume":"45","author":"Koeijers","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idnow.2026.105312_bb0045","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.cmi.2025.04.029","article-title":"Revisiting diagnostics: discarding the urine dipstick is way overdue","volume":"31","author":"Bodilsen","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.idnow.2026.105312_bb0050","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1515\/cclm-2024-0070","article-title":"The EFLM European urinalysis guideline 2023","volume":"62","author":"Kouri","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1016\/j.idnow.2026.105312_bb0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.idnow.2026.105312_bb0060","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/antibiotics12111611","article-title":"Urinary tract infections in men in primary care in Catalonia, Spain","volume":"12","author":"Fern\u00e1ndez-Garc\u00eda","year":"2023","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0065","doi-asserted-by":"crossref","DOI":"10.3399\/BJGPO.2023.0207","article-title":"Acute cystitis in men\u2014a nationwide study from primary care: antibiotic prescriptions, risk factors, and complications","volume":"8","author":"S\u00e6tre","year":"2024","journal-title":"BJGP Open"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211098","article-title":"Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men","volume":"14","author":"Montelin","year":"2019","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.idnow.2026.105312_bb0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1756287215581556","article-title":"Effectiveness and safety of nitrofurantoin in outpatient male veterans","volume":"7","author":"Ingalsbe","year":"2015","journal-title":"Ther Adv Urol"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/fampra\/cmac068","article-title":"Guidelines for the management of male urinary tract infections in primary care: a lack of international consensus\u2014a systematic review of the literature","volume":"40","author":"Soudais","year":"2023","journal-title":"Fam Pract"},{"key":"10.1016\/j.idnow.2026.105312_bb0085","article-title":"Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105312_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euros.2025.03.010","article-title":"Classification of urinary tract infections in 2025: moving beyond uncomplicated and complicated","volume":"75","author":"Bonkat","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0095","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.urology.2010.02.052","article-title":"Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility","volume":"76","author":"Koeijers","year":"2010","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European Association of Urology guidelines on urological infections: summary of the 2024 guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.idnow.2026.105312_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2334-8-12","article-title":"Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis","volume":"8","author":"Etienne","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.idnow.2026.105312_bb0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0302-2838(03)00158-1","article-title":"Total and free serum prostate specific antigen levels during the first month of acute prostatitis","volume":"43","author":"Gam\u00e9","year":"2003","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0094-0143(05)70374-8","article-title":"The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration","volume":"24","author":"Tchetgen","year":"1997","journal-title":"Urol Clin North Am"},{"issue":"3\u20134","key":"10.1016\/j.idnow.2026.105312_bb0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11255-006-0073-7","article-title":"Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk","volume":"38","author":"Battikhi","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.idnow.2026.105312_bb0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.12688\/f1000research.24094.3","article-title":"Frequency and clinical significance of prostatic involvement in men with febrile urinary tract infection: a prospective observational study","volume":"9","author":"Arjunlal","year":"2020","journal-title":"F1000Res"},{"issue":"12","key":"10.1016\/j.idnow.2026.105312_bb0130","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/cid\/ciad070","article-title":"Antimicrobials for 7 or 14 days for febrile urinary tract infection in men: a multicenter noninferiority double-blind, placebo-controlled, randomized clinical trial","volume":"76","author":"Lafaurie","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0135","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1128\/JCM.00717-10","article-title":"Blood cultures for men with febrile urinary tract infection","volume":"48","author":"Smithson","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0140","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/JCM.00425-10","article-title":"Should blood cultures be performed for patients with acute prostatitis?","volume":"48","author":"Etienne","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jiac.2021.02.014","article-title":"Comparison of the clinical characteristics of community-acquired acute pyelonephritis between male and female patients","volume":"27","author":"Jang","year":"2021","journal-title":"J Infect Chemother"},{"issue":"9","key":"10.1016\/j.idnow.2026.105312_bb0150","first-page":"321","article-title":"Bacteremic urinary infection in men: comparative study with bacteremic pyelonephritis in women","volume":"109","author":"Bastida Vil\u00e1","year":"1997","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"10.1016\/j.idnow.2026.105312_bb0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2014.12.005","article-title":"Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations","volume":"68","author":"Pilatz","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.idnow.2026.105312_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eursup.2017.01.003","article-title":"Acute and chronic epididymitis","volume":"16","author":"\u00c7ek","year":"2017","journal-title":"Eur Urol Suppl"},{"issue":"30","key":"10.1016\/j.idnow.2026.105312_bb0165","doi-asserted-by":"crossref","first-page":"2101012","DOI":"10.2807\/1560-7917.ES.2022.27.30.2101012","article-title":"High antimicrobial resistance in urinary tract infections in male outpatients in routine laboratory data, Germany, 2015 to 2020","volume":"27","author":"Salm","year":"2022","journal-title":"Euro Surveill"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0170","article-title":"GMC study group. Bacterial epidemiology and antibiotic resistance rates in male urinary tract infections in France, 2019-2023","volume":"55","author":"Reissier","year":"2025","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.idnow.2026.105312_bb0175","unstructured":"Medqual [Internet]. n.d. Donn\u00e9es de la mission PRIMO [PRIMO mission data] (cited June 10, 2026). Available from: https:\/\/medqualville.antibioresistance.fr\/ [In French]."},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0180","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jac\/dkab392","article-title":"Computerized decision support system (CDSS) use for surveillance of antimicrobial resistance in urinary tract infections in primary care","volume":"77","author":"Delory","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105312_bb0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000074526","article-title":"Penetration of antimicrobial agents into the prostate","volume":"49","author":"Charalabopoulos","year":"2003","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2026.105312_bb0190","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.2000587","article-title":"The immune system fails to mount a protective response to gram-positive or gram-negative bacterial prostatitis","volume":"205","author":"Lupo","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.idnow.2026.105312_bb0195","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.chom.2024.04.015","article-title":"Variability in cell division among anatomical sites shapes Escherichia coli antibiotic survival in a urinary tract infection mouse model","volume":"32","author":"Amoura","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"10","key":"10.1016\/j.idnow.2026.105312_bb0200","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.35.10.1947","article-title":"Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning","volume":"35","author":"Nix","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105312_bb0205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jmsacl.2023.12.003","article-title":"Therapeutic drug monitoring of glycopeptide antimicrobials: an overview of liquid chromatography-tandem mass spectrometry methods","volume":"31","author":"Cafaro","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0215","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1128\/AAC.48.5.1441-1453.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue","volume":"48","author":"M\u00fcller","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0220","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","article-title":"Tissue concentrations: do we ever learn?","volume":"61","author":"Mouton","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idnow.2026.105312_bb0225","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"19","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0230","first-page":"322","article-title":"Effect of urine concentration versus tissue concentration of ampicillin and mecillinam on bacterial adherence in the rat bladder","volume":"18","author":"Frimodt-M\u00f8ller","year":"1981","journal-title":"Invest Urol"},{"issue":"11\u221212","key":"10.1016\/j.idnow.2026.105312_bb0235","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.micinf.2004.05.023","article-title":"Host subversion by formation of intracellular bacterial communities in the urinary tract","volume":"6","author":"Anderson","year":"2004","journal-title":"Microbes Infect"},{"issue":"1 Suppl","key":"10.1016\/j.idnow.2026.105312_bb0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(01)01130-X","article-title":"Dynamic interactions between host and pathogen during acute urinary tract infections","volume":"57","author":"Schilling","year":"2001","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/CMR.00019-07","article-title":"Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis","volume":"21","author":"Jacobsen","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"728","key":"10.1016\/j.idnow.2026.105312_bb0250","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.3399\/BJGP.2022.0354","article-title":"Nitrofurantoin failure in males with an uncomplicated urinary tract infection: a primary care observational cohort study","volume":"73","author":"Platteel","year":"2023","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.idnow.2026.105312_bb0255","article-title":"No clinical benefit to treating male urinary tract infection longer than seven days: an outpatient database study. Open forum","volume":"6(6):ofz216","author":"Germanos","year":"2019","journal-title":"Infect Dis"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/antibiotics9050211","article-title":"Nitrofurantoin failure in elderly men: a retrospective observational study","volume":"9","author":"Wolterink","year":"2020","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.idnow.2026.105312_bb0265","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/02813432.2020.1794409","article-title":"Different antibiotic regimes in men diagnosed with lower urinary tract infection\u2014a retrospective register-based study","volume":"38","author":"Kornf\u00e4lt Isberg","year":"2020","journal-title":"Scand J Prim Health Care"},{"issue":"3","key":"10.1016\/j.idnow.2026.105312_bb0270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/antibiotics5030031","article-title":"Reconsultation and antimicrobial treatment of urinary tract infection in male and female patients in general practice","volume":"5","author":"Tandan","year":"2016","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02813432.2020.1718301","article-title":"Retrospective study of men with E. Coli UTI treated with an oral antibiotic, and risk for a new prescription or hospital admission due to UTI","volume":"38","author":"Jans\u00e5ker","year":"2020","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.idnow.2026.105312_bb0280","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/IDR.S209255","article-title":"Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not\u2014a retrospective cohort study","volume":"12","author":"Jans\u00e5ker","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.idnow.2026.105312_bb0285","article-title":"Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study","volume":"360","author":"Crellin","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.idnow.2026.105312_bb0290","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/jac\/dkw178","article-title":"Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis","volume":"71","author":"Seroy","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0295","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12879-016-1888-1","article-title":"Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study","volume":"16","author":"Matthews","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.idnow.2026.105312_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004157","article-title":"Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study","volume":"3","author":"Qiao","year":"2013","journal-title":"BMJ Open"},{"issue":"2\u20133","key":"10.1016\/j.idnow.2026.105312_bb0310","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000085625","article-title":"Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study","volume":"51","author":"Bonfiglio","year":"2005","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0315","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"Senol","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.idnow.2026.105312_bb0320","author":"European Association of Urology (EAU) [Internet]"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0325","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","article-title":"Practice guidelines for the management of adult community-acquired urinary tract infections","volume":"48","author":"Caron","year":"2018","journal-title":"Med Mal Infect"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0335","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/0036554021000026988","article-title":"Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up","volume":"35","author":"Ulleryd","year":"2003","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","author":"van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.idnow.2026.105312_bb0345","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/IDR.S178183","article-title":"Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial","volume":"12","author":"Lojanapiwat","year":"2019","journal-title":"Infect Drug Resist."},{"issue":"3","key":"10.1016\/j.idnow.2026.105312_bb0350","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1473-3099(21)00407-2","article-title":"The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden","volume":"22","author":"Edlund","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.idnow.2026.105312_bb0355","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20166","article-title":"Oral \u03b2-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source","volume":"3","author":"Sutton","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.idnow.2026.105312_bb0360","article-title":"Fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections: a multicenter, retrospective cohort study. Open forum","volume":"9(1):ofab620","author":"Wald-Dickler","year":"2022","journal-title":"Infect Dis"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0365","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.idnow.2026.105312_bb0370","volume":"10(Suppl 2):ofad500.002","author":"Seo","year":"2023","journal-title":"Infect Dis"},{"key":"10.1016\/j.idnow.2026.105312_bb0375","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/IDR.S163280","article-title":"Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review","volume":"11","author":"Jans\u00e5ker","year":"2018","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.idnow.2026.105312_bb0380","article-title":"The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. Coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study","volume":"22(1):478","author":"Hansen","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.idnow.2026.105312_bb0385","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks\u2019 treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.idnow.2026.105312_bb0390","unstructured":"HAS [Internet]. 2019. Antibioth\u00e9rapie des infections \u00e0 ent\u00e9robact\u00e9ries et \u00e0 Pseudomonas aeruginosa chez l'adulte : place des carbap\u00e9n\u00e8mes et de leurs alternatives [Antibiotic therapy for Enterobacteriaceae and Pseudomonas aeruginosa infections in adults: role of carbapenems and their alternatives] (updated March 13, 2023; cited June 10, 2026). Available from: https:\/\/www.has-sante.fr\/jcms\/c_2968915\/fr\/antibiotherapie-des-infections-a-enterobacteries-et-a-pseudomonas-aeruginosa-chez-l-adulte-place-des-carbapenemes-et-de-leurs-alternatives [In French]."},{"key":"10.1016\/j.idnow.2026.105312_bb0395","article-title":"Assessing clinical cure of empirical piperacillin\/tazobactam for ESBL urinary tract infections (ACCEPT-UTI)","volume":"5(3):dlad055","author":"Stefanos","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/antibiotics9020061","article-title":"Carbapenem-sparing strategies for ESBL producers: when and how","volume":"9","author":"Karaiskos","year":"2020","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105312_bb0410","doi-asserted-by":"crossref","unstructured":"Dinh A, Duran C, Singh S, Tesmoingt C, Bouabdallah L, Hamon A, et al. Real-life temocillin use in Greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study. JAC Antimicrob Resist. 2022;5(1):dlac132. doi:https:\/\/doi.org\/10.1093\/jacamr\/dlac132. Erratum in: JAC Antimicrob Resist. 2023;5(1):dlad002. doi:https:\/\/doi.org\/10.1093\/jacamr\/dlad002.","DOI":"10.1093\/jacamr\/dlad002"},{"issue":"1","key":"10.1016\/j.idnow.2026.105312_bb0415","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10096-019-03701-0","article-title":"Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase\u2013producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis","volume":"39","author":"Senard","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.idnow.2026.105312_bb0420","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.idnow.2026.105312_bb0425","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/jac\/dkac448","article-title":"Comparison of the relative efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study","volume":"78","author":"Chen","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0430","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1046\/j.1464-410x.1999.00252.x","article-title":"A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age","volume":"84","author":"Eickhoff","year":"1999","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.idnow.2026.105312_bb0435","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/bjs.1800710921","article-title":"The aetiology and management of acute epididymitis","volume":"71","author":"Redfern","year":"1984","journal-title":"Br J Surg"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0440","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1258\/ijsa.2011.011023","article-title":"Clinical effectiveness group, British Association for Sexual Health and HIV. BASHH UK guideline for the management of epididymo-orchitis, 2010","volume":"22","author":"Street","year":"2011","journal-title":"Int J STD AIDS"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0445","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1439-0272.2007.00823.x","article-title":"Diagnosis and therapy of acute prostatitis, epididymitis and orchitis","volume":"40","author":"Ludwig","year":"2008","journal-title":"Andrologia"},{"issue":"9","key":"10.1016\/j.idnow.2026.105312_bb0450","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/14656566.2022.2062228","article-title":"Advances in the antibiotic management of epididymitis","volume":"23","author":"Khastgir","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.idnow.2026.105312_bb0455","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1464-410x.2001.02216.x","article-title":"Acute epididymitis","volume":"87","author":"Luzzi","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.idnow.2026.105312_bb0460","unstructured":"Aotearoa New Zealand [Internet]. n.d. Epididymo-Orchitis [cited June 10, 2026]. Available from: https:\/\/sti.guidelines.org.nz\/syndromes\/epididymo-orchitis\/."},{"issue":"4","key":"10.1016\/j.idnow.2026.105312_bb0465","first-page":"1","article-title":"Prise en charge des prostatites aigu\u00ebs [Management of acute prostatitis]","volume":"41","author":"Kutchukian","year":"2023","journal-title":"EMC - Urologie"},{"key":"10.1016\/j.idnow.2026.105312_bb0470","author":"EAU [Internet]"},{"issue":"2","key":"10.1016\/j.idnow.2026.105312_bb0475","first-page":"167","article-title":"The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society","volume":"21","author":"Abrams","year":"2002","journal-title":"NeurourolUrodyn"},{"issue":"7","key":"10.1016\/j.idnow.2026.105312_bb0480","first-page":"F394","volume":"34","author":"Ploussard","year":"2024","journal-title":"Prog Urol"},{"issue":"16","key":"10.1016\/j.idnow.2026.105312_bb0485","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.purol.2013.05.009","article-title":"Int\u00e9r\u00eat de l\u2019utilisation du PSA dans la prise en charge des prostatites: revue de la litt\u00e9rature [The value of PSA in the management of prostatitis: a literature review]","volume":"23","author":"Bruy\u00e8re","year":"2013","journal-title":"Prog Urol"},{"key":"10.1016\/j.idnow.2026.105312_bb0490","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejim.2022.09.024","article-title":"Short versus long course therapy in the treatment of febrile urinary tract infections in men based on serum PSA values","volume":"106","author":"Monz\u00f3n","year":"2022","journal-title":"Eur J Intern Med"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:45:31Z","timestamp":1787705131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991926000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666991926000692"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105312","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated guidelines for management of community-acquired urinary tract infections in adult men by the French infectious disease society (SPILF)","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105312"}}